Holen Sie sich die Stockscreener-App
282.85
2.26%
-6.54
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - BioSpace
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - The Globe and Mail
Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What Does the Alnylam-Inceptive AI Deal Entail - Kavout
Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets - World Business Outlook
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations - simplywall.st
Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region - Contract Pharma
Alnylam Stock Is Running Its Own Race. Here’s What That Means for Your Portfolio. - Trefis
Alnylam expands Genesis Pharma collaboration in Europe - MSN
Alnylam expands Genesis Pharma deal in Europe (ALNY:NASDAQ) - Seeking Alpha
Genesis Pharma expands Alnylam partnership to Nordic markets - Investing.com
Genesis Pharma expands Alnylam partnership to Nordic markets By Investing.com - Investing.com South Africa
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development - Business Wire
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region - Stock Titan
Alnylam Stock Is Running Its Own Race. Here's What That Means for Your Portfolio. - Trefis
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts - Yahoo Finance
Fiera Capital Corp Purchases 16,916 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam to collaborate with Inceptive to use AI for RNAi therapy development - MSN
Alnylam Slides as Investors Refocus on Near-term Amvuttra Growth After Recent AI-deal Headlines - Moomoo
Bloom Energy, Astera Labs, Alnylam, Reddit could be among next adds to S&P 500 - MSN
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500 - Barron's
City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 5%What's Next? - MarketBeat
Alnylam slides as investors refocus on near-term Amvuttra growth after recent AI-deal headlines - Quiver Quantitative
Capital International Inc. CA Sells 16,086 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities - Seeking Alpha
Los Angeles Capital Management LLC Buys 80,658 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
Capital Research Global Investors Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors - MarketBeat
Capital International Ltd. CA Sells 10,556 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Capital International Sarl Has $47.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Westfield Capital Management Co. LP Acquires 5,536 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Savant Capital LLC Sells 5,677 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Bank of New York Mellon Corp Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CIBC Asset Management Inc Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright reiterates Alnylam stock Buy rating at $510 By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Valuation Check As US$2b AI RNAi Collaboration With Inceptive Nucleics Gains Attention - Yahoo Finance
Harvest Fund Management Co. Ltd Has $4.10 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ALNY Reiterated by HC Wainwright & Co. -- Maintains Price Target at $510 - GuruFocus
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Benzinga
Alnylam, Inceptive ink AI deal potentially worth $2B - BioPharma Dive
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development - Yahoo Finance
Alnylam, Inceptive Sign AI-RNAi Drug Discovery Deal Worth Up To $2bn - Citeline News & Insights
ATTR treatment landscape heats up as clinical progress gathers pace - The Pharma Letter
Westpac Banking Corp Purchases 3,956 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus - simplywall.st
Alnylam signs $2 billion AI pact with Inceptive - The Pharma Letter
Alnylam (ALNY) Partners with Inceptive Nucleics for $2B Innovati - GuruFocus
3.11%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):